Company / Gross Margin
Vivos Therapeutics, Inc. Gross Margin History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
60.0%
FY2025
5-year range
59.9% / 79.7%
FY2021-FY2025
Trend
+0.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Gross Margin returned to growth in FY2025 after 3 years of decline, reaching 60.0%.
Based on SEC 10-K filings.
60.0% in FY2025 with a 5-year CAGR of -16.0%.
Declined from 62.5% to 60.0% over the past 2 years.
Gross Margin over time
Growth rates
- 3-Year Change
- -14.7pp
- 5-Year Change
- -16.0pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, gross margin increased 0.1% year-over-year.
- Peak gross margin was recorded in FY2021.
- Lowest gross margin in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 60.0% | +0.1% |
| FY2024 | 59.9% | -4.1% |
| FY2023 | 62.5% | -16.2% |
| FY2022 | 74.7% | -6.3% |
| FY2021 | 79.7% | +4.9% |
| FY2020 | 76.0% | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026